Start with the part that is not a preference.
Withdrawal from alcohol and from benzodiazepines can kill you. Seizures, delirium tremens, cardiovascular collapse. Someone physically dependent on either who stops abruptly without medical supervision is taking a real mortal risk.
Withdrawal from opioids is agonising and rarely fatal in itself. Stimulant withdrawal is psychologically brutal and not physically dangerous in the same way.
Most families have this backwards, because heroin withdrawal is what films depict and a bottle of wine looks domestic. If the substance is alcohol or benzodiazepines, stopping is the dangerous part and requires medical supervision wherever it happens.
That is the safety floor. Everything below assumes it is met.
The finding that reframes the whole question
Wakeman and colleagues (2020) followed 40,885 people with opioid use disorder across six treatment pathways and measured overdose.
Buprenorphine or methadone was associated with a 76% reduction in overdose at three months and 59% at twelve.
Detoxification was not associated with any reduction in overdose. Neither was intensive behavioural health treatment, nor naltrexone.
Detox, on its own, did not reduce the outcome that matters most.
Sordo and colleagues (2017) supply the mechanism: mortality is markedly elevated in the first four weeks after leaving treatment. Tolerance falls during a period of abstinence; a return to a previous dose afterwards is a different and far more dangerous event than it was before.
So a detox that is not connected to sustained treatment does not merely fail to help. For opioids specifically, it creates a window of elevated risk.
The question is not where the detox happens. It is what the detox is connected to.
When home detox is genuinely appropriate
With medical supervision, and where the clinical picture allows:
Alcohol dependence in the mild-to-moderate range, in someone medically stable, with no history of seizures or delirium tremens, no significant co-occurring illness, and a sober responsible adult present throughout.
Benzodiazepine tapers, which are often long, gradual and well-suited to being done at home under supervision precisely because they take weeks.
Situations where the alternative is nothing — where the person will not go to a facility, and the honest choice is a supervised home detox or continued use.
The advantages are real: privacy, no facility, no visitor log, and — often underrated — the person practises the early days in the environment they will actually live in, rather than in a protected setting they have to leave.
When it is the wrong call
A history of seizures or delirium tremens. Significant medical or psychiatric comorbidity. Polysubstance dependence, especially alcohol with benzodiazepines. No reliable adult present. A home environment where the substance is available or someone else is using. Any prior withdrawal that went badly.
None of these is a judgment about the person. They are risk factors, and they are the reason this is a clinical assessment rather than a family decision.
What to insist on, wherever it happens
A physician assessment before anything starts, not a phone triage.
Medical monitoring appropriate to the substance and the history.
A written plan for escalation — who is called, and at what threshold.
Medication where indicated, and for the length the evidence supports rather than a fixed short course. The Wakeman duration data is unambiguous: overdose rates fell from 6.4% among those treated 1–30 days to 1.1% among those treated beyond 180 days.
And, above all, what happens next. Detox is not treatment. It is the removal of a substance from a body. If nothing follows it, the research says you have bought a period of elevated risk.
When they will only agree to do it at home
This is the situation families are most often actually in, and it deserves a straight answer rather than a lecture.
Someone has agreed to stop, but will not go anywhere. The choice is not between home detox and inpatient. It is between a supervised home detox and nothing.
In that case, take the supervised home detox — provided the medical assessment permits it. An imperfect plan that the person will actually consent to beats an ideal plan they refuse. The risk of continued drinking at current levels is not zero, and it is often being weighed as though it were.
Two conditions make it defensible. A physician has assessed them and judged home withdrawal safe for this particular history. And something is arranged to follow it — because the evidence above says a detox connected to nothing buys a period of elevated risk rather than progress.
If the assessment says no, that is not a negotiating position. Alcohol and benzodiazepine withdrawal kill people, and a refusal to go to hospital does not change the physiology.
What the days actually look like
For a supervised alcohol detox at home, typically: a physician assessment and baseline bloods; medication, usually a tapering benzodiazepine schedule, prescribed and dispensed in controlled amounts rather than handed over as a box; observation across the first 72 hours, which is when seizure risk peaks; vitamins, fluids and food, which matter more than people expect; and a clear escalation threshold with a named person to call.
The person is usually not comfortable and is often frightened. Having somebody present who has done this before is the difference between an ordinary difficult week and a week that ends in a decision to stop halfway.
The decision, put simply
If the substance is alcohol or benzodiazepines, get a medical assessment before anything is decided. That is not a scheduling matter.
If the assessment permits it and the home environment is sound, in-home detox offers real privacy advantages and the person learns the first days where they will actually live.
But do not choose a detox in isolation. Choose the six months that follow it, and then decide where the first week happens.
References
- Wakeman SE, Larochelle MR, Ameli O, et al. (2020). Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. JAMA Network Open. 10.1001/jamanetworkopen.2019.20622
- Sordo L, Barrio G, Bravo MJ, et al. (2017). Mortality risk during and after opioid substitution treatment. BMJ, 357, j1550. 10.1136/bmj.j1550
Read more about Rehab Placement.
